“…Some gene mutations or rearrangements are responsible for the development of aggressive and treatment-resistant types of leukemia. [12][13][14][15][16] Patients with ALL should be screened for the following genetic aberrations: deletion of IKZF1, PAX5, CDKN2A, CDKN2B, P2RY8-CRLF2, EGR, rearrangements of ABL1, ABL2, CSF1R, PDGFRbeta, IGH, CRLF2, EPOR, NTRK3, BCR-ABL1, AFF1 (mll), AFF1-KMT2A (MLL-AF4), ETV6-RUNX1 (TEL-AML1), TCF3, mutation of JAK2, as well as hypo-or hyperdiploidy. 9 Detection of the genetic background that contributes to poor prognosis remains a challenge and may be a basis for developing new therapeutic targets.…”